Skip to main content
. Author manuscript; available in PMC: 2019 Jul 26.
Published in final edited form as: Cell. 2018 Jun 21;174(3):549–563.e19. doi: 10.1016/j.cell.2018.05.052

Figure 5. LSD1 inhibition stimulates anti-tumor T cell immunity, which depends on dsRNA recognition and IFN-β production.

Figure 5

(A and B) Tumor growth (A) and survival curves (B) of immunocompetent mice inoculated with 500k scramble or LSD1 KO B16 cells.

(C and D) Tumor growth (C) and survival curves (D) of immunocompetent or immunodeficient (TCRα KO) mice inoculated with 500k scramble or LSD1 KO B16 cells.

(E and F) Tumor growth (E) and survival curves (F) of immunocompetent mice inoculated with 500k scramble, LSD1 KO, MDA5 KO, or LSD1/MDA5 DKO B16 cells.

(G) Tumor growth of immunocompetent mice inoculated with 500k scramble, LSD1 KO, IFN-β KO, or LSD1/IFN-β DKO B16 cells.

(H and I) Representative images (H) and quantification (I) of lung metastasis in immunocompetent mice receiving 200k scramble or LSD1 KO B16 cells intravenously.

Data represent two independent experiments (A–F). Error bars represent SEM of individual mice per group in one experiment. *p<0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, not significant, as determined by unpaired t-test (A and I), Log-rank test (B, D and F), or 2-way ANOVA (C, E and G).